A Multiple Dose Study Of PF-06678552 In Healthy Subjects

• Drug: PF-06678552
  
  PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
• Drug: Placebo
  
  PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
• Drug: PF-06678552
  
  PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
• Drug: Placebo
  
  PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

• Experimental: Cohort 1
  
  Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo
• Experimental: Cohort 2
  
  Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo
• Experimental: Cohort 3
  
  Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo
• Experimental: Cohort 4
  
  Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo
• Experimental: Cohort 5
  
  Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo
• Experimental: Cohort 6
  
  Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
  Interventions:
  

  • Drug: PF-06678552
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects of non-childbearing potential.
• Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight >50 kg
• Low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)